Repatha for FH: Off-Label Use, Evidence, Risks, and Clinical Trade-Offs

What Is the FDA-Approved Indication for Evolocumab in FH?

The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy. A separate approval covers homozygous familial hypercholesterolemia (HoFH) in patients aged 13 and older. This makes evolocumab one of only two PCSK9 inhibitors with a dedicated HoFH label, though it requires clear documentation of the diagnosis before most payers will authorize it. FDA label for Repatha

HeFH Approval: Adults Only

For heterozygous FH, the FDA indication specifies adult patients. A clinician prescribing evolocumab to a child under 13 with genetically confirmed HeFH is operating off-label, even though the drug carries a pediatric indication for the homozygous form in patients 13 and older. The distinction matters for insurance prior authorization and for informed-consent conversations with families.

HoFH Approval: Age 13 and Older

The TESLA Part B trial (N=50) established efficacy in homozygous FH patients as young as 12 years at enrollment, which formed the basis for the adolescent extension of the HoFH label. Mean LDL-C fell by 30.9% from baseline in the evolocumab arm versus a 0.3% increase in placebo at 12 weeks (P<0.0001). PMID 25524718

Critically, patients with two null LDLR variants showed attenuated response because evolocumab works by preventing PCSK9 from degrading LDL receptors. No functioning receptors means no meaningful LDL lowering. Prescribing evolocumab monotherapy to a confirmed null/null HoFH patient is technically within the approved age range but may produce negligible clinical benefit, which is a distinct trade-off to discuss before starting therapy.

What Does "Off-Label" Actually Mean Here?

Off-label use is legal and common. The FDA does not restrict physician prescribing once a drug is approved; it restricts manufacturer promotion. For evolocumab in FH specifically, off-label territory includes:

• HeFH in patients under 13 years of age
• HoFH in patients under 13 (the label starts at 13)
• Use in adults without a confirmed FH diagnosis or ASCVD event where the clinical rationale rests on Lp(a) elevation or severe isolated LDL-C burden alone
• Statin-intolerant patients with FH who have never had a cardiovascular event and whose 10-year ASCVD risk is below 7.5% (a payer gray zone rather than a safety concern)

The American College of Cardiology and American Heart Association 2022 guidelines state explicitly: "For patients with primary severe hypercholesterolemia (LDL-C ≥190 mg/dL), adding a PCSK9 inhibitor is reasonable if the LDL-C response to maximally tolerated statin plus ezetimibe is insufficient." This wording captures most FH patients without requiring the prescriber to use the word "off-label," but the underlying approval status does not change. ACC/AHA 2022 Cholesterol Guideline Focused Update

Why Payers Still Deny Claims

Insurance denial for evolocumab in FH is common even when the prescriber believes use is guideline-supported. The two most frequent denial reasons are:

1. Insufficient documentation of statin maximization: most plans require at least two statins trialed at maximum tolerated dose before approving a PCSK9 inhibitor.
2. Unconfirmed FH diagnosis: a Dutch Lipid Clinic Network score or genetic test result documenting a pathogenic LDLR, APOB, or PCSK9 variant typically satisfies payer requirements.

Providing both items upfront reduces prior-authorization failure rates substantially.

The Evidence Base for Evolocumab in FH: How Strong Is It?

The evidence in FH is among the most dense of any off-label cardiovascular use. Multiple randomized controlled trials, a cardiovascular outcomes trial with hard endpoints, and guideline endorsement from four major societies all point in the same direction.

FOURIER: The Landmark Outcomes Trial

FOURIER (N=27,564) randomized patients with established atherosclerotic cardiovascular disease and LDL-C ≥70 mg/dL on optimized statin therapy to evolocumab 140 mg every two weeks or 420 mg monthly versus placebo. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% (HR 0.85, 95% CI 0.79-0.92, P<0.001). LDL-C dropped from a median baseline of 92 mg/dL to 30 mg/dL, a 59% reduction. PMID 28304224

FOURIER did not specifically enroll an FH-only cohort, but a pre-specified subgroup analysis of patients with baseline LDL-C ≥190 mg/dL showed consistent benefit without evidence of heterogeneity. Patients who likely had FH based on LDL burden derived at least comparable relative risk reduction to the overall population.

RUTHERFORD-2: HeFH-Specific RCT

RUTHERFORD-2 (N=329) enrolled adults with genetically confirmed or clinically diagnosed HeFH and LDL-C ≥100 mg/dL on stable statin therapy. At 12 weeks, evolocumab 140 mg every two weeks reduced LDL-C by 59.2% versus a 0.5% reduction with placebo (P<0.001), and the 420 mg monthly regimen produced a 61.3% reduction. PMID 25282519

This trial established the pharmacodynamic rationale for HeFH use. No hard cardiovascular endpoint data exist specifically in an HeFH-only trial, which is one reason the GRADE evidence for adult HeFH sits at Moderate rather than High.

Pediatric Data: Thin but Directionally Clear

For children with HeFH under 13, the primary reference point is a 52-week open-label study (NCT02624869, N=104, ages 10-17) that showed a 44.5% mean LDL-C reduction from baseline. No serious adverse events beyond injection-site reactions were observed over the study period. Long-term safety data in prepubertal children are absent, which anchors the GRADE rating for this population at Low. PMID 30236391

The EAS Familial Hypercholesterolaemia Studies Collaboration consensus states: "Earlier and more intensive LDL-lowering reduces cumulative atherosclerotic burden in FH and may have lifetime benefits that outweigh the current evidence gaps." This framing supports off-label pediatric prescribing in high-risk children while acknowledging that certainty remains lower than in adults.

Dosing Protocols for FH: On-Label vs. Off-Label Scenarios

The approved adult dosing is straightforward. Off-label pediatric dosing follows the logic of the adolescent HoFH approval rather than a formally tested pediatric HeFH dose-finding study.

Standard Adult FH Dosing

• HeFH (adults): 140 mg subcutaneously every 14 days, or 420 mg once monthly via three consecutive 140 mg injections within 30 minutes using the prefilled autoinjector.
• HoFH (13 and older): same regimen; some guidelines allow titration to monthly 420 mg if the every-two-week schedule is impractical.

The drug requires refrigeration at 36-46 degrees Fahrenheit. It may be stored at room temperature (up to 77 degrees F) for up to 30 days. Missed doses should be administered within 7 days of the scheduled date; otherwise, the patient resumes the original schedule.

Off-Label Pediatric HeFH Dosing

No FDA-approved pediatric dose for HeFH exists in children under 13. Clinicians who prescribe in this context typically use the adolescent weight-based guidance extrapolated from the NCT02624869 study data: 140 mg every two weeks if weight is 40 kg or greater, with clinical judgment applied below that threshold. Lipid specialist involvement is appropriate for any patient in this age group.

Monitoring After Initiation

The 2022 ACC/AHA guidelines recommend a fasting lipid panel 4-12 weeks after starting a PCSK9 inhibitor to confirm LDL-C response, then every 3-12 months. For pediatric off-label use, many lipid specialists shorten the interval to every 3 months for the first year given the thinner safety database.

Risks and Safety Profile: What the Data Show

Evolocumab is generally well-tolerated across its approval history. The safety signals that exist are mild and reversible. No long-term organ-toxicity signal has emerged in trials running up to five years.

Common Adverse Effects

• Injection-site reactions: 3.2% with evolocumab versus 2.9% with placebo in FOURIER. Most are mild erythema or pruritus resolving within 24-48 hours.
• Nasopharyngitis: 6.4% versus 5.5%, a numerically higher rate that has not been attributed to a mechanistic immunologic effect.
• Upper respiratory infection: 4.8% versus 4.3%.

None of these rates reached statistical significance as a safety concern in the trial, but they inform the informed-consent conversation.

The Neurocognitive Question

Early post-marketing reports raised concerns about memory impairment with PCSK9 inhibitors. The FDA required a formal neurocognitive study. EBBINGHAUS (N=1,204, embedded in FOURIER) found no significant difference in neurocognitive testing scores between evolocumab and placebo over a median 19 months using a validated cognitive test battery. PMID 28530227

The FDA updated labeling in 2017 to reflect this finding. Clinicians can counsel patients that the available controlled evidence does not support a neurocognitive risk, though anecdotal reports continue to surface.

Very Low LDL-C: Is There a Floor?

Patients in FOURIER who achieved LDL-C below 20 mg/dL (roughly 17% of the evolocumab arm) showed no increase in adverse events compared with those with higher achieved levels, including no excess in hemorrhagic stroke, new-onset diabetes, or adrenal insufficiency. The body's endogenous cholesterol synthesis, which is independent of dietary LDL uptake, appears sufficient to meet cellular needs even at very low circulating LDL-C. PMID 28304224

Specific FH Risk Considerations

For HoFH null/null variants, the risk profile is not worse than placebo but the benefit is near zero. Prescribing evolocumab to this subgroup without LDL apheresis represents a missed opportunity rather than a harm, but it may delay more effective therapy and carries a cost burden.

For pediatric patients, the absence of five-year or ten-year follow-up data means that effects on hormonal development, liver function, and cardiovascular maturation are inferred rather than measured. One 52-week study is not a long-term safety database.

Guideline Position: What Four Major Societies Say

Every major guideline endorses PCSK9 inhibitor use in FH when statin plus ezetimibe does not achieve LDL-C targets. The differences are in thresholds.

ACC/AHA 2022

The focused update supports adding a PCSK9 inhibitor in adults with LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe if they have established ASCVD, and in patients with LDL-C ≥100 mg/dL and multiple high-risk features including confirmed FH. The guideline does not restrict use to on-label indications. ACC/AHA 2022

EAS Consensus 2019

The European Atherosclerosis Society consensus panel recommends that FH patients with ASCVD or at very high risk (defined as ≥2 additional risk factors or 10-year risk ≥10%) achieve LDL-C below 55 mg/dL. For most HeFH patients on maximally tolerated statin plus ezetimibe who remain above this threshold, a PCSK9 inhibitor is explicitly recommended. PMID 31497854

AACE/ACE 2022

AACE endorses PCSK9 inhibitors as second-line agents after statin plus ezetimibe in very high-risk patients, with LDL-C targets of below 55 mg/dL for extreme-risk patients (which includes recurrent ASCVD events on maximum lipid-lowering therapy). This guidance broadly captures the FH-plus-ASCVD population. AACE 2022 Lipid Guidelines

Pediatric FH: The FH Foundation and AHA Statement

The FH Foundation and the AHA pediatric committee both support lipid-lowering therapy initiation in children with FH as young as age 8 for statins. For PCSK9 inhibitors, the AHA scientific statement on pediatric FH acknowledges that off-label use may be appropriate in high-risk children who fail statin plus ezetimibe, provided families receive full informed consent about the evidence gaps. PMID 33955782

Practical Clinical Decision Framework for FH Patients

The decision to prescribe evolocumab in an FH patient who does not neatly fit the FDA label involves three steps.

Step 1: Confirm the FH diagnosis. Use Dutch Lipid Clinic Network criteria, Simon Broome criteria, or genetic testing. A pathogenic variant in LDLR, APOB, or PCSK9 gene shifts the decision from "possible FH" to "confirmed FH" and strengthens the payer authorization case.

Step 2: Document statin maximization. Two statins at highest tolerated dose, or a documented reason for statin intolerance (for example, CK elevation above 10 times the upper limit of normal on two separate agents), should be in the chart before submitting a prior authorization. Ezetimibe 10 mg daily should also be documented as tried.

Step 3: Calculate residual cardiovascular risk. A patient with confirmed HeFH, LDL-C of 160 mg/dL on atorvastatin 80 mg plus ezetimibe, and a first-degree relative who had MI at age 42 is at very high lifetime risk. The absolute risk reduction from adding evolocumab is larger for this patient than for someone with milder residual LDL elevation and no family history of premature ASCVD.

Patients who meet all three criteria have a clear clinical rationale for evolocumab regardless of whether the prescribing context is technically on-label or off-label.

Cost, Access, and Alternatives

Evolocumab carries a list price near $5,800 per month without insurance, though manufacturer copay cards bring out-of-pocket costs to as low as $5 per month for commercially insured patients who meet program criteria. The Amgen patient assistance program covers uninsured patients below specified income thresholds.

Alirocumab (Praluent) carries a similar mechanism and comparable clinical evidence, with an FDA-approved HeFH indication in adults and a recently added pediatric indication for HeFH in patients 8 and older. For a child aged 8-12 with HeFH, alirocumab may be the on-label choice, which simplifies payer authorization even if the clinical pharmacology is nearly identical to evolocumab. FDA alirocumab label

Inclisiran, a small interfering RNA that targets PCSK9 mRNA, is approved for adults with HeFH and primary hyperlipidemia and is administered only twice yearly after two loading doses. It is not yet approved for pediatric FH.

Lomitapide and mipomersen are approved specifically for HoFH in adults and offer a receptor-independent mechanism that works even in null/null LDLR patients where evolocumab is ineffective.